News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 28, 2021--Industry veteran CFO joins at critical juncture--
-
Jun 14, 2021--ARU-2801 is a potentially curative gene therapy in development for individuals with hypophosphatasia (HPP)--
-
May 27, 2021--Data demonstrates promise for lead program, ARU-1801, as potentially curative treatment for sickle cell disease--
-
May 12, 2021--Data suggest individualized melphalan dosing prior to ARU-1801 infusion may improve patient outcomes--
-
Apr 27, 2021--Data demonstrates treatment with ARU-1801 resulted in meaningful improvements in clinical outcomes for participants with severe sickle cell disease--